

Warning: fsockopen(): unable to connect to mdg.mdgms.com:80 (Connection timed out) in `/www/eba_portal/modules/lib/sxp_includes/mdgCommunication.inc` on line **118**

Warning: fputs() expects parameter 1 to be resource, bool given in `/www/eba_portal/modules/lib/sxp_includes/mdgCommunication.inc` on line **268**

Warning: feof() expects parameter 1 to be resource, bool given in `/www/eba_portal/modules/lib/sxp_includes/mdgCommunication.inc` on line **273**

Warning: fclose() expects parameter 1 to be resource, bool given in `/www/eba_portal/modules/lib/sxp_includes/mdgCommunication.inc` on line **275**

BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

Company

2024/10/18 22:00:00

biotechne

Price
71.24
USD

Difference ↑
1.55%(1.09)



Contact Details

BIO-TECHNE CORP. Tel: +1-612-379-8854
 -- Fax: +1-612-656-4400
 614 McKinley Place NE Web: <http://www.bio-techne.com>
 55413-2610 Minneapolis E-mail: info@bio-techne.com

Company Profile

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Financial figures, Fiscal year: from 01.07. to 30.06.

Financial figures	2024		2023		2022	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	617,419,000		621,482,000		605,556,000	
Common stock capital		1,582,000		1,576,000		392,000
Fixed assets	2,195,771,000		2,112,233,000		1,765,472,000	
Equity capital of a company		2,068,850,000		1,966,516,000		1,701,011,000
Cash and cash equivalents	151,791,000		180,571,000		172,567,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		159,379,000		128,509,000		176,018,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		584,961,000		638,690,000		493,999,000
Different income		-		-		-
Other liabilities		13,157,000		10,919,000		17,239,000
Total assets	2,813,190,000	2,813,190,000	2,733,715,000	2,733,715,000	2,371,028,000	2,371,028,000

Balance notes

	2024	2023	2022
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,100	3,050	3,000
Equity ratio	73.54%	71.94%	71.71%
Debt-equity ratio	35.98%	39.01%	39.45%

Others

	2024	2023	2022
Tax Expense Rate	9.47%	15.71%	12.70%

BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock

Income statement

	2024	2023	2022
Turnover	1,159,060,000	1,136,702,000	1,105,599,000
Net income	168,072,000	285,193,000	271,930,000
EBIT	194,889,146	322,238,565	293,079,188
Operating income before taxes	185,689,000	338,659,000	301,386,000
Cash Flow	298,981,000	254,393,000	325,272,000
Net interest income	-25,940,000	-11,258,000	-16,867,000
Research and development expenses	96,664,000	92,493,000	87,140,000
Income taxes	17,584,000	53,217,000	38,287,000
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	344,316	343,209	339,382

Board of Directors

Members of Management Board

Robert Baumgartner	Chairman of Board of Directors
Alpna Seth	Member of Board of Directors
Joseph Keegan	Member of Board of Directors
Judith Klimovsky	Member of Board of Directors
Randolph Steer	Member of Board of Directors
Roeland Nusse	Member of Board of Directors
Rupert Vessey	Member of Board of Directors
John Higgins	Member of Board of Directors
Julie Bushman	Member of Board of Directors
Kim Kelderman	Chairman of Managing Board
Gary Latham	Member of Executive Committee
Jim Hippel	Member of Executive Committee